TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

SULFACETAMIDE SODIUM

SULFACETAMIDE SODIUM
Infectious Disease Approved 1971-12-22
8
Indications
--
Phase 3 Trials
54
Years on Market

Details

Status
Prescription
First Approved
1971-12-22
Routes
OPHTHALMIC, TOPICAL
Dosage Forms
OINTMENT, LOTION, SOLUTION/DROPS

SULFACETAMIDE SODIUM Approval History

Loading approval history...

What SULFACETAMIDE SODIUM Treats

3 indications

SULFACETAMIDE SODIUM is approved for 3 conditions since its original approval in 1971. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Conjunctivitis
  • Ocular Infections
  • Trachoma
Source: FDA Label
๐Ÿ”ฌ

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...
โญ

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
๐Ÿ“Š

Trial Timeline

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

SULFACETAMIDE SODIUM FDA Label Details

Pro

Indications & Usage

Sulfacetamide Sodium Ophthalmic Solution, USP 10% is indicated for the treatment of conjunctivitis and other superficial ocular infections due to susceptible microorganisms, and as an adjunctive in systemic sulfonamide therapy of trachoma: Escherichia coli, Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus (viridans group), Haemophilus influenzae, Klebsiella species, and Enterobacter species. Topically applied sulfonamides do not provide adequate coverage against Neisseria species, Serratia marcescens and Pseudomonas aeruginosa . A significant percentage of staphylococcal isolates...

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.